Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects? | Zendy

Misghina Weldegiorgis | Zendy; Dick de Zeeuw | Zendy; Jamie P. Dwyer | Zendy; Peter G. M. Mol | Zendy; Hiddo J.L. Heerspink | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Author(s) -

Misghina Weldegiorgis,

Dick de Zeeuw,

Jamie P. Dwyer,

Peter G. M. Mol,

Hiddo J.L. Heerspink

Publication year - 2017

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.09590916

Subject(s) - medicine , irbesartan , renal function , urology , diabetic nephropathy , creatinine , losartan , dialysis , hazard ratio , albuminuria , confidence interval , kidney , angiotensin ii , blood pressure

RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both are assumed to reflect changes in the filtration capacity of the kidney, drug effects, if present, are attributed to kidney protection. However, decisions to start RRT are not only on the basis of filtration capacity of the kidney, but also on other factors. We therefore compared the time to RRT with the time to a fixed eGFR threshold and assessed the effect of the renoprotective drug irbesartan on both components.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research